Vertex Inc. (VERX)
Vertex: A Chance To Buy The Dip (Upgrade)
Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software product with strong net revenue retention. Despite a slight revenue outlook cut, adjusted EBITDA guidance was raised, and a $150 million buyback program was launched, signaling management confidence.
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings
Vertex Pharmaceuticals Incorporated remains a leader in cystic fibrosis treatments, fueling robust cash flow and funding a promising pipeline expansion. VRTX is seeing early but accelerating revenue from new products Casgevy and Journavx, with non-CF revenue projected to reach 16-20% by 2032. The VRTX pipeline includes potential blockbusters in kidney disease, with key FDA decisions expected in 2026, supporting long-term growth prospects.
Vertex (VERX) Earnings Expected to Grow: Should You Buy?
Vertex (VERX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Growth Fund Dumps $25 Million in Vertex Stock as Weak Quarter Hit Returns
Pennsylvania-based Conestoga Capital Advisors sold 855,435 Vertex shares for an estimated $24.8 million based on average prices for the quarter ended September 30. The change represents 0.4% of 13F reportable assets under management for the period.
Wall Street Analysts Believe Vertex (VERX) Could Rally 44.47%: Here's is How to Trade
The mean of analysts' price targets for Vertex (VERX) points to a 44.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More
This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear growth catalysts for 2025 and beyond. Caution is urged on popular income-focused ETFs like SPYI and ULTY, as structural flaws and capped upside may limit long-term wealth compounding.
Vertex Inc.: Moving To The Sidelines As Near-Term Growth Expectations Get Reset
I downgrade Vertex (VERX) to Hold due to macro headwinds and ERP migration delays impacting near-term growth outlook. Cloud momentum and e-invoicing adoption remain strong, but on-premise weakness and slower customer expansion weigh on results. FY25 guidance was cut, and growth reacceleration is now less certain, resetting investor expectations and hurting sentiment.
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)
The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF franchise remains a dominant, reliable growth engine, with new revenue ramps from Casgevy and Journavx set to accelerate diversification. VRTX stock valuation is attractive: forward P/E is favorable versus peers, growth prospects are strong, and insider buying signals management confidence at current prices.
Here's What Key Metrics Tell Us About Vertex (VERX) Q2 Earnings
Although the revenue and EPS for Vertex (VERX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VERX) Q2 Earnings and Revenues Surpass Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.
